In this work, we deprioritized testing with DNMT3A because it has been reported that this enzyme can act as both an oncogene and as a tumor suppressor gene, at least in lung cancer (it remains to be tested as to whether this paradox of DNMT3A applies to other cancers) [8]. The gene discussed is DNMT3A; the disease is lung carcinoma.